Alpha Cognition Inc. Common Stock
ACOG
About: Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.
Employees: 57
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
200% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 3 (+2) [Q2]
80% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 5
64% more capital invested
Capital invested by funds: $32.4M [Q1] → $53.4M (+$20.9M) [Q2]
18% more funds holding
Funds holding: 22 [Q1] → 26 (+4) [Q2]
3.87% less ownership
Funds ownership: 39.57% [Q1] → 35.7% (-3.87%) [Q2]
63% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 8
Financial journalist opinion
